Personalized Treatment for Relapsed T-Cell Blood Cancer
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a precision medicine approach for patients with T-cell acute lymphoblastic leukemia (a blood cancer) that has come back after treatment or didn't respond to chemotherapy. The trial uses genetic testing of cancer cells to match patients with targeted drug combinations tailored to their specific cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 15 years old (under 18 only allowed in France)
- You have T-cell acute lymphoblastic leukemia that has relapsed (returned) once or twice, or is refractory (not responding to chemotherapy)
- You have cancer cells in your blood or bone marrow that can be tested, or have already had genetic testing done at a reference lab in France, Spain, or the Netherlands in the past 10 days
- Your overall health status is reasonably good (able to care for yourself with minimal assistance)
- You cannot be pregnant or breastfeeding, and must use effective contraception if of childbearing potential
- You don't have active hepatitis B, hepatitis C, or HIV, and your liver and kidney function are adequate for chemotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This trial tests the combination of two drugs, venetoclax and decitabine, for people whose T-cell acute lymphoblastic leukemia has come back or hasn't responded to standard treatment. The goal is to see if this combo can help when other treatments haven't worked.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
This trial tests a combination of three drugs (capivasertib, venetoclax, and dexamethasone) for children and young adults whose blood cancer has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new LAL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.